Influence of type of treatment on the well-being of Spanish patients with schizophrenia and their caregivers

References

• Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005;162:441–9.
   PubMed Web of Science ®Google Scholar
• Anthony WA. Recovery from mental illness: the guiding vision of the mental health service system in the 1990s. Psychosocial Rehabil J 1993;16:11–23.
   Google Scholar
• Tandon R. Safety and tolerability: how do newer generation “atypical” antipsychotics compare? Psychiatr Q 2002;73: 297–311.
   PubMed Web of Science ®Google Scholar
• Pereira S, Pinto R. A survey of the attitudes of chronic psychiatric patients living in the community toward their medication. Acta Psychiatr Scand 1997;95:464–8.
   PubMed Web of Science ®Google Scholar
• Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001;179:290–9.
   PubMed Web of Science ®Google Scholar
• Bhanji NH, Chouinard G, Margolese HC. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Eur Neuropsychopharmacol 2004;14:87–92.
   PubMed Web of Science ®Google Scholar
• Llorca PM, Bouhours P, Moreau-Mallet V; French investigators group. Improved symptom control, functioning and satisfaction in French patients treated with long-acting injectable risperidone. Encephale 2008;34:170–8.
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. New Engl J Med 2005;353:487–97.
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21:419–29.
   PubMed Web of Science ®Google Scholar
• Haro JM, Kamath SA, Ochoa S, Novick D, Rele K, Fargas A, . The Clinical Global Impression–Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand 2003; 107(s416):16–23.
   Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–76.
   PubMed Web of Science ®Google Scholar
• Greiner W, Weijnen T, Nieuwenhuizen M, Oppe S, Badia X, Busschbach J, . A single European currency for EQ-5D health states. Results from a six-country study. Eur J Health Econ 2003;4:222–31.
   PubMedGoogle Scholar
• Gort AM, March J, Gómez X, de Miguel M, Mazarico S, and Ballesté J. Escala de Zarit reducida en cuidados paliativos. Med Clin (Barcelona) 2005;124:651–3.
   PubMed Web of Science ®Google Scholar
• Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, . Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457–65.
   PubMed Web of Science ®Google Scholar
• Csernansky JG, Mahmoud R, Brenner R; Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New Engl J Med 2002;346:16–22.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med 2005;353:1209–23.
   PubMed Web of Science ®Google Scholar
• Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 2003;64:1308–15.
   PubMed Web of Science ®Google Scholar
• Remington G, Kwon J, Collins A, Laporte D, Mann S, Christensen B. The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia. Schizophr Res 2007;90:229–37.
   PubMed Web of Science ®Google Scholar
• Lam Y, Velligan D, DiCocco M. Comparative assessment of antipsychotic adherence by concentration monitoring, pill count and self–report [abstract]. Schizophr Res 2003;60 (Suppl 1):313.
   PubMedGoogle Scholar
• Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. J Am Med Assoc 1996;276:1253–8.
   PubMed Web of Science ®Google Scholar
• Woods SW, Ziedonis DM, Sernyak MJ, Diaz E, Rosenheck RA. Characteristics of participants and nonparticipants in medication trials for treatment of schizophrenia. Psychiatr Serv 2000;51:79–84.
   PubMedGoogle Scholar
• Almond S, Knapp M, Francois C, Toumi M, Brugha T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 2004;184:346–51.
   PubMed Web of Science ®Google Scholar
• Haro JM, Edgell ET, Jones PB, Alonso J, Gavart S, Gregor KJ, . The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment. Acta Psychiatr Scand. 2003;107:222–32.
   PubMed Web of Science ®Google Scholar
• Ciudad A, Prieto L, Olivares JM, Montejo AL, Ros S, Novick D; Grupo Español del Estudio SOHO. The European schizophrenia outpatient health outcomes (SOHO) study: baseline findings of the Spanish sample. Actas Esp Psiquiatr 2004;32:227–35.
   PubMedGoogle Scholar
• Parellada E, Kouniakis FA, Siurkute A, Schreiner A, Don L. Survey of safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional prospective study. Abstract 89, presented at the European Meeting of Psychiatry, 24–28 January 2009, Lisbon, Portugal.
   Google Scholar
• Moore TA, Covell NH, Essock SM, Miller AL. Real-world antipsychotic treatment practices. Psychiatr Clin North Am 2007;30:401–16.
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Duchesne I, Mehnert A, Janagap C, Eerdekens M. Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. J Clin Psychiatry 2004;65:531–6.
   PubMed Web of Science ®Google Scholar
• Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125–32.
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Maldonado J, Caqueo-Urízar A, Kavanagh DJ. Burden of care and general health in families of patients with schizophrenia. Soc Psychiatry Psychiatr Epidemiol 2005;40:899–904.
   PubMed Web of Science ®Google Scholar
• Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist 1980;20:649–55.
   PubMed Web of Science ®Google Scholar
• Ohaeri JU. The burden of caregiving in families with mental illness: a review of 2002. Services research and outcomes. Curr Opin Psychiatry 2003;16:457–465.
   Web of Science ®Google Scholar
• Han C, Lee BH, Kim YK, Lee HJ, Kim SH, Kim L, . Satisfaction of patients and caregivers with long-acting injectable risperidone and oral atypical antipsychotics. Prim Care Community Psychiatr 2005;10:118–124.
   Google Scholar
• Olivares JM, Rodriguez-Morales A, Diels J, Povey M, Jacobs A, Zhao Z, . Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009;24:287–96.
   PubMed Web of Science ®Google Scholar
• Prieto L, Sacristán JA, Hormaechea JA, Casado A, Badia X, Gómez JC. Psychometric validation of a generic health-related quality of life measure (EQ-5D) in a sample of schizophrenic patients. Curr Med Res Opin 2004;20:827–35.
   PubMed Web of Science ®Google Scholar